The Zhitong Finance App learned that in the Hong Kong stock market on August 20, Beishui traded net sales of HK$10.412 billion. Among them, Hong Kong Stock Connect (Shanghai) had net sales of HK$5.111 billion and Hong Kong Stock Connect (Shenzhen) had net sales of HK$5.301 billion.
The individual stocks that Beishui Net bought the most were Alibaba-W (09988), Kuaishou-W (01024), and Kingsley Biotechnology (01548). The individual stocks sold the most by Beishui Net were Yingfu Fund (02800), CSPC Group (01093), and Tencent (00700).
Hong Kong Stock Connect (Shanghai) active trading stocks
Hong Kong Stock Connect (Shenzhen) active trading stocks
Alibaba-W (09988) received a net purchase of HK$2.205 billion. Alibaba announced results after the market. Revenue for the first quarter of fiscal year 2027 was 268.95 billion yuan, up 9% year on year, estimated at 268.52 billion yuan; adjusted net profit of 20.72 billion yuan, estimated at 25.58 billion yuan; adjusted revenue per ADS was 8.52 yuan, estimated at 11.28 billion yuan. For the quarter ended June 30, capital expenditure was $67.678 billion, up 75% from RMB38.676 billion in the same period last year.
Kuaishou-W (01024) received a net purchase of HK$1,143 million. Kuaishou revealed in its financial report that Keling AI's revenue for the second quarter exceeded 850 million yuan, up more than 200% year on year and up 30.8% month on month; core commercial revenue, which includes online marketing services and other services centered on e-commerce and Keling AI, increased 7.4% year over year, for a total of 26.845 billion yuan.
Pharmaceutical stocks were clearly divided today. Kingsley Biotech (01548) and Pharmaceutical Biotech (02269) received net purchases of HK$205 million and HK$91.83 million respectively, while CSPC Group (01093) had a net sale of HK$1,091 million. On August 19, Moderna and MSD announced that the personalized mRNA cancer vaccine in combination with Keytruda met the analysis standards during the phase III melanoma trial period. This is the world's first personalized mRNA cancer vaccine that has proven effective in late-stage trials. The analysis indicates that with the clinical launch of leading overseas products, a large number of tumor mRNA pipelines will enter the clinical development stage around the world, and demand for upstream raw materials and OEM production will continue to explode.
Yingfu Fund (02800) had a net sale of HK$2,758 billion. Societe Generale Securities pointed out that the core drivers of the current rise in Hong Kong stocks are still undervaluation repairs, capital rebalancing, and a reversal of extreme sentiment, and a complete reversal driven by widespread profit revisions has yet to be formed. Huatai Securities also said that in the future, a further increase in valuation will require an increase in AI progress and profit fulfillment expectations of Hong Kong stock companies, or stronger domestic demand policies and repair expectations.
In addition, SMIC (00981) and Tencent (00700) had net sales of HK$350 million and HK$408 million respectively.